O-叔丁基-L酪氨酸甲酯 | 52616-82-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: O-叔丁基-L酪氨酸甲酯
• 英文名称: O-tert-butyl-L-tyrosine methyl ester
• 英文别名: Tyr(tBu)-OMe；methyl (2S)-2-amino-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoate
• CAS: 52616-82-7
• 化学式: C₁₄H₂₁NO₃
• 分子量: 251.326
• InChiKey: AORVWDJGVFCGOW-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  O-叔丁基-L酪氨酸甲酯 在 sodium tetrahydroborate 、 sodium periodate 、 四氧化锇 、 1-羟基苯并三唑 、 N,N'-二异丙基碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 Cbz-α(HOCH2CH2)-Pro-Tyr(Bu-t)-OMe
  参考文献：
  名称：

  新型肽β-turn模拟物的设计与合成

  摘要：

  描述了新型螺环单元（7）的立体定向合成及其在固相方法中的结构，该结构为免疫显性九肽（1）的构象锁定类似物。

  DOI：

  10.1039/c39880001447
• 作为产物：
  描述：

  Z-L-酪氨酸甲酯 在 palladium on activated charcoal 硫酸 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 42.0h， 生成 O-叔丁基-L酪氨酸甲酯
  参考文献：
  名称：

  Flexible and Convergent Total Synthesis of Cyclotheonamide B

  摘要：

  A convergent approach using two key intermediates, segment A [a L-proline-L-alpha-hydroxy-beta-homoarginine-D-phenylalanine (Pro-hArg-D-Phe) tripeptide] and segment B [a vinylogous L-tyrosine-L-2,3-diaminopropanoic acid (vTyr-Dpr) dipeptide], was developed for the synthesis of cyclotheonamide B (Scheme 1). The starting compound for the preparation of the hArg moiety 7, the predominant part of segment A, was N-alpha-(benzyloxycarbonyl)-N-omega , N(omega)'bis(tert-butyloxycarbonyl)-l-arginine methyl ester (15, Scheme 2), which was converted into the aldehyde 16 and subsequently homologated using [tris(methylthio)methyl]lithium as a carboxylic acid anion equivalent. Coupling with properly protected Pro and D-Phe derivatives gave smoothly the desired Pro-hArg-D-Phe tripeptide derivative 24. The key feature of segment B, i.e., the L-tyrosine-derived alpha,beta-unsaturated gamma-amino acid 4, was prepared by a Wadsworth-Emmons olefination of the aldehyde 29 (Scheme 3) derived from N-(tert-butyloxycarbonyl), O-tert-butyl-L-tyrosine methyl ester (28). Selective N-(tert-butyloxycarbonyl) removal in the presence of the aryl tert-butyl ether present in the fully protected segment B, i.e., 32, was achieved by treatment with trimethylsilyl triflate/2,6-lutidine to give vTyr-Dpr dipeptide derivative 34 in quantitative yield. Coupling of the key intermediates 24 and 34 using 2-(1H-benzotriazol-l-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) afforded the protected linear pentapeptide 35 in high yield (Scheme 4). Treatment of 35 with Pd(PPh3)(4)/morpholine resulted in simultaneous removal of the C-terminal allyl group and the N-terminal allyloxycarbonyl group to yield 36. Ring closure was effected under dilution conditions by treatment with TBTU/1-hydroxybenzotriazole/4-(dimethylamino and gave the protected cyclopentapeptide 37 in 61% yield. Oxidation of the hydroxyl group with Dess-Rlartin periodinane (24 h, 40 degrees C) in the presence of tert-butyl alcohol gave 38, which was then subjected to O,N-deprotection with trifluoroacetic acid/thioanisole. Subsequent HPLC purification afforded cyclotheonamide B in an overall yield of 1.8% in 17 steps.

  DOI：

  10.1021/jo961447m

文献信息

• Exploration of zinc-binding groups for the design of inhibitors for the oxytocinase subfamily of M1 aminopeptidases
  作者：Sofia Tsoukalidou、Magdalini Kakou、Ioannis Mavridis、Despoina Koumantou、Vito Calderone、Marco Fragai、Efstratios Stratikos、Athanasios Papakyriakou、Dionisios Vourloumis

  DOI：10.1016/j.bmc.2019.115177

  日期：2019.12

  of the enzymes via strong interactions with the catalytic zinc(II) atom and, while achieving increased potency, they suffer in selectivity. Continuing our earlier efforts on weaker zinc(II) binding groups (ZBG), like the 3,4-diaminobenzoic acid derivatives (DABA), we herein synthesized and biochemically evaluated analogues of nine potentially weak ZBGs, based on differential substitutions of functionalized

  M1氨基肽酶的催产素酶亚家族由三个成员ERAP1，ERAP2和IRAP组成，这些成员起着重要的生物学作用，包括在驱动人类免疫应答的抗原肽的产生中发挥关键作用。它们代表了免疫系统药理学控制的新兴目标，尽管缺乏选择性抑制剂阻碍了这些努力。大多数以前探索的小分子结合剂通过与催化性锌（II）原子的强相互作用而靶向酶的活性位点，并且在获得增强的效价的同时，它们也具有选择性。继续我们先前对弱锌（II）结合基团（ZBG）（如3,4-二氨基苯甲酸衍生物（DABA））的研究，我们在此合成并通过生物化学方法评估了9种潜在的弱ZBG的类似物，基于官能化的吡啶酮和吡啶硫酮骨架，烟酸，异烟酸，氨基苯甲酸和肼基苯甲酸的差异取代。两种类似物与金属蛋白酶（MMP-12）的结晶学分析显示出意料之外的结合拓扑，与观察到的亲和力一致。我们的结果表明，该化合物作为ERAP1，ERAP2和IRAP抑制剂的效力主要是由占据活性位点的特异性口袋及其在酶中的正确方向决定的。
• Access to Enantiopure α-Hydrazino Acids for <i>N</i>-Amino Peptide Synthesis
  作者：Chang Won Kang、Matthew P. Sarnowski、Yassin M. Elbatrawi、Juan R. Del Valle

  DOI：10.1021/acs.joc.6b02718

  日期：2017.2.3

  amide substituents have received less attention due, in part, to the lack of practical synthetic strategies. Here, we report the synthesis of α-hydrazino acids derived from 19 out of the 20 canonical proteinogenic amino acids and demonstrate their use in the solid-phase synthesis of N-amino peptide derivatives.

  α-肽的骨干N-甲基化已被广泛用于增强亲本序列的生物利用度和生物活性。杂原子肽酰胺取代基受到的关注较少，部分原因是缺乏实用的合成策略。在这里，我们报告了20种典型蛋白氨基酸中19种衍生的α-肼基酸的合成，并证明了它们在N-氨基肽衍生物的固相合成中的用途。
• Novel high affinity quinoline-based kinase ligands
  申请人：Deng Yongqi

  公开号：US20080045568A1

  公开（公告）日：2008-02-21

  Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

  基于喹啉的细胞周期蛋白依赖激酶2抑制剂，包括这些抑制剂的组合物，以及使用这些抑制剂和抑制剂组合物的方法。这些抑制剂和包括它们的组合物对治疗疾病或疾病症状有用。该发明还提供了制备CDK-2抑制剂化合物的方法，抑制CDK-2的方法，以及治疗疾病或疾病症状的方法。
• 2-Bromoamides as synthons for pseudopeptides containing aminodicarboxy units
  作者：Ferruccio D'Angeli、Paolo Marchetti、Severe Salvador、Gianfranco Balboni

  DOI：10.1039/c39930000304

  日期：——

  The monoalkylating and enantioselective behaviour of a chiral 2-bromoamide allows the synthesis of pseudopeptides in which a dipeptide component is changed into an aminodicarboxy moiety, with overall retention of configuration.

  手性2-溴酰胺的单烷基化和对映选择性行为使得合成伪肽成为可能，其中二肽部分被转变成氨基二羧基结构单元，并且总体构型得以保留。
• [EN] THERAPEUTIC CYCLIC COMPOUNDS AS IMMUNOMODULATORS<br/>[FR] COMPOSÉS CYCLIQUES THÉRAPEUTIQUES UTILISÉS EN TANT QU'IMMUNOMODULATEURS
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2016142835A1

  公开（公告）日：2016-09-15

  The present invention relates to cyclic compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

  本发明涉及公式（I）的环状化合物及其用于抑制程序性细胞死亡1（PD-1）信号通路和/或通过抑制由PD-1、PD-L1或PD-L2诱导的免疫抑制信号治疗疾病。